New LDL-C

Quest Diagnostics Moves to Convenient Nonfasting Cholesterol Testing with Improved Method for Assessing Heart Disease Risk and Aiding Treatment Decisions

Quest – SECAUCUS, N.J.Sept. 7, 2017 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that all of the company’s cholesterol test services that involve estimates of low-density lipoprotein cholesterol (LDL-C) now use a novel calculation shown to improve the accuracy of testing for levels of LDL-C, a key marker of risk of cardiovascular disease. (Read More)